Exercise of options, Directors Dealing, Issue of equity
Faron Pharmaceuticals Ltd. (“Faron”) Exercise of options, Directors Dealing Issue of equity Company announcement, August 31, 2023 at 14:00 p.m. BST / 16:00 p.m. EEST TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical- stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that it has received notifications from option holders to exercise 2015B options over 18,022 in the Company at an exercise price of EUR 2.90 (approx. GBP 2.48) per share, raising gross proceeds of